Background
==========

In two Phase III randomized trials in MM, Ipi improved median overall survival (OS) \[[@B1],[@B2]\]. Here, we evaluate OS and characterize post-Ipi treatment patterns among long-term survivors from a single-institution cohort of patients (pts) treated with Ipi.

Methods
=======

Through a search of institutional databases, we identified 766 pts with MM treated with Ipi between 1/1/2003 and 12/31/2013. As of 4/1/2014, 96 pts have survived ≥2 yrs, measured from first dose of Ipi. OS was calculated utilizing the Kaplan-Meier method. Disease control was defined as the duration from initiation of Tx until initiation of subsequent systemic Tx or death.

Results
=======

With a median follow-up of 17mo (range 0-9yr), the median OS for the entire cohort of 766 pts was 15mo, with a 2-yr OS of 41%. Of the 80 pts with OS ≥2 yrs post-Ipi for whom data are available, 75% (n = 60/80) remain alive and 30% (n = 24/80) remain progression-free following Ipi, with median Ipi disease control of 15mo (range: 3 to 107+mo). Among pts with progression (n = 56), 57% exhibited disseminated progression, 29% oligometastatic progression, and 15% CNS-only progression. The most frequent Tx at first progression was locoregional (n = 29), employed at a median of 11mo post-Ipi (range: 3 to 55mo) and associated with median 15+mos disease control (range 1 to 73+mo) (table [1](#T1){ref-type="table"}). In pts requiring post-Ipi systemic Tx, long-term disease control was observed across multiple systemic Tx\'s (table [2](#T2){ref-type="table"}).

###### 

Pts receiving locoregional Tx at first progression.

  -------------------------------------------------------------------
  Locoregional Tx              \# pts        \# pts achieving ≥1yr\
                                             disease control
  ---------------------------- ------------- ------------------------
  **CNS, surgery and/or RT**   9/80 (11%)    5/9 (56%)

  **Non-CNS, surgery**         11/80 (14%)   8/11 (73%)

  **Non-CNS, RT**              6/80 (8%)     3/6 (50%)

  **Ablation**                 2/80 (3%)     1/2 (50%)
  -------------------------------------------------------------------

###### 

Post-Ipi Systemic Txs.

  ----------------------------------------------------------------------------------
  Post-Ipi\                  \# pts        \# pts achieving ≥1yr disease control\*
  Systemic Tx                              
  -------------------------- ------------- -----------------------------------------
  **Cytotoxic Therapy**      11/80 (14%)   5/10 (50%)

  **Anti-PD-1/PD-L1**        16/80 (20%)   11/15 (73%)

  **BRAF inhibitor**         10/80 (13%)   7/9 (78%)

  **Ipi re-induction**       18/80 (23%)   5/16 (31%)

  **Other clinical trial**   13/80 (16%)   1/13 (8%)
  ----------------------------------------------------------------------------------

\*pts with ongoing disease control and \<1yr follow up excluded

Conclusion
==========

Within this single-institution cohort, the median OS and 2-yr OS were greater than reported previously in Phase III trials \[[@B1],[@B2]\]. Potential reasons for this survival advantage include: referral bias, heterogeneous Ipi dosing/schedule, and access to subsequent trials (i.e. anti-PD-1/PD-L1, BRAF inhibitor). The majority of long-term survivors required subsequent Tx, however prolonged disease control was achieved with a range of Tx\'s. Pts who experience oligometastatic/CNS-only progression following Ipi may achieve prolonged disease control with locoregional Tx alone.
